Click here for slides on this topic


Incretin mimetics

A class of agents for the treatment of type 2 diabetes. Incretin mimetics mimic the enhancement of glucose-dependent insulin secretion, as well as other glucoregulatory actions of incretin hormones. The dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are incretins.
The following content matched the glossary term: Incretin mimetics

No Increased Risk of Pancreatic Cancer With Incretins

Top

Data presented at EASD 2015 show no causal association between the use of incretin based therapies—DPP-4 inhibitors and GLP-1 receptor agonists—and pancreatitis or pancreatic cancer

CompanionSetType2DiabetesMedications

Top

Patient education companion set featuring handouts on DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and medications used to treat type 2 diabetes (English and Spanish)

Medications Used To Treat Type 2 Diabetes

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose.

HARMONY 3: 104-week trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride

Top

Ahrén B, Johnson SL, Stewart M, et al; for the HARMONY 3 Study Group. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014;37(8):2141-2148.

Managing the Patient With Type 2 Diabetes and Heart Failure

Top

.style1 FONT FAMILY Arial, Helvetica, sans serif COLOR #004685

Medicamentos para el tratamiento de la diabetes tipo 2

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose—in Spanish.

Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study

Top

Faillie J-L, Azoulay L, Patenaude V, Hillaire-Buys D, Suissa S. Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study. BMJ. 2014;348:g2780. doi 10.1136/bmj.g2780.

ADA 2016 Type 2 Diabetes Pharmacologic Therapy

Top

Pharmacologic treatment options for type 2 diabetes from the 2016 ADA guidelines

American Diabetes Association (ADA) Nutrition Guidelines for Adults With Diabetes

Top

Diabetes management guidelines for nutrition from the American Diabetes Association (ADA)

1 2 3 Next 

Slide Library Results

Search Results for: Incretin mimetics Slides Found: 12
Exenatide: Clinical Pharmacology
Exenatide: Effects on Glycemic Control in Combination With Current Oral Therapies
Exenatide: Proportion of Patients Achieving A1C <=7%
Exenatide: Effect on the Beta-Cell
Change in Body Weight Following 82 Weeks of Exenatide Treatment
Effect of Exenatide + TZD on Blood Glucose in Patients With Type 2 Diabetes
Effect of Exenatide + TZD on Body Weight in Patients With Type 2 Diabetes
Frequent Adverse Events in Diabetic Patients Treated With DPP-4 Inhibitors
Change in A1C for GLP-1 Analogues vs Control in Diabetic Adults
Change in A1C for DPP-4 Inhibitors vs Control in Diabetic Adults
Change in A1C for DPP-4 Inhibitors vs Control in Diabetic Adults (cont)
ADA Nutrition Guidelines: Priorities for Nutrition Management By Medication